$2.600
-0.151 (-5.80%)收盤時
CGEN 資訊
CGEN 事件
Compugen Reports Q2 Revenue of $2.6M, Exceeds Expectations
Reports Q2 revenue $2.6M, consensus $1.28M. As of June 30 Compugen had approximately $125.3M in cash, cash equivalents, short-term bank deposits, and investment in marketable securities. Compugen expects that its cash and cash-related balances will be sufficient to fund its operating plans into 2029.
US Treasury Yields Rise, Market Sentiment Weighed Down
With earnings season mostly in the rearview mirror outside of Nvidia'sQ1 results this week, the macro component has returned to dominate the market narrative, and the global "rate shock" is clearly weighing on sentiment. US 10-year Treasury Note yield closed above 4.6% for the first time since early 2025 and the 30-year reached 5.15% - both up by over 50 basis points from late February just before the start of the Iran war - as markets continue to fret over stagflation backdrop, sending major indices in the red for much of the day.Similar to Friday, Monday's notable rotation away from the AI disruption trade continued as Semiconductors were largely lower while Software names saw some notable dip-buying. Names like Cognizant, ServiceNow, and EPAM Systemswere among the leaders in the S&P 500. In turn, the AI infrastructure buildout "winners" like Micronand Sandiskwere among the 10 weakest stocks in the benchmark.In the opening hour of the evening session, U.S. equity futures are modestly higher, with traders responding to the latest Truth Social post from President Trump announcing a delay to resumption of strikes by US military on Iranian infrastructure with hopes for a deal that addresses Tehran's nuclear ambitions. S&P e-minis and Nasdaq 100 contracts are up about 0.2% while July WTI Crude Oil is down 2% below $102.50 per barrel.Check out this evening's top movers from around Wall Street, compiled by The Fly.HIGHER AFTER EARNINGS -Agilysysup 13.6%ALSO HIGHER -Penguin Solutionsup 3.5% after naming David Heard, President of Network Infrastructure at Nokia, to BoardNomad Foodsup 1.6% after insider buyDOWN AFTER EARNINGS -XP Inc.down 5.1%Bally's Corporationdown 2.5%Yalla Groupdown 2.5%ALSO LOWER -Compugendown 3.5% after equity offering
Compugen Files $400M Mixed Securities Shelf
Compugen files $400M mixed securities shelf
Compugen Q1 Revenue $2.2M, Cash Sufficient Until 2029
Reports Q1 revenue $2.2M vs. $2.3M last year. Compugen expects that its cash and cash-related balances will be sufficient to fund its operating plans into 2029. The company has no debt. "Q1 2026 reflects continued execution across all of our programs in line with our strategic priorities," said CEO Eran Ophir. "With enrollment progressing across all COM701 MAIA-ovarian trial sites, we remain on track for having the median progression-free survival at the interim analysis by Q1 2027, a key potential inflection point for COM701 as a maintenance therapy in a patient population with significant unmet medical need and no current standard of care. Our partner AstraZeneca continues to broadly advance rilvegostomig. In addition, we continue to advance the Gilead-partnered GS-0321 Phase 1 trial. Our solid financial position with cash runway expected into 2029, based on our current plans, enables us to advance our differentiated immuno-oncology pipeline and leverage our AI/ML powered computational discovery platform Unigen, to discover novel ways to activate the immune system against cancer. I remain encouraged by the progress of our fully owned programs, strengthened by validating partnerships with AstraZeneca and Gilead, which together offer approximately $1B in potential milestones plus royalties."
Compugen Reports Q4 Revenue of $67.3M
Reports Q4 revenue $67.3M vs. $1.5M last year. "We delivered important progress in 2025, highlighted by the extension of our cash runway into 2029 through a non-dilutive monetization agreement with AstraZeneca for rilvegostomig," said Eran Ophir, Ph.D., President and CEO of Compugen. "This strategic transaction strengthens our cash position while preserving the potential for significant long-term value of a multi-billion-dollar asset being advanced by AstraZeneca across 10 Phase 3 clinical trials in lung, gastrointestinal and endometrial cancers with further clinical data anticipated from Phase 1/2 clinical trials in 2026."
本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。



